共查询到20条相似文献,搜索用时 46 毫秒
1.
Mikael K. Schnizler Katrin Schnizler Xiang-ming Zha Duane D. Hall John A. Wemmie Johannes W. Hell Michael J. Welsh 《The Journal of biological chemistry》2009,284(5):2697-2705
The acid-sensing ion channel 1a (ASIC1a) is widely expressed in central and
peripheral neurons where it generates transient cation currents when
extracellular pH falls. ASIC1a confers pH-dependent modulation on postsynaptic
dendritic spines and has critical effects in neurological diseases associated
with a reduced pH. However, knowledge of the proteins that interact with
ASIC1a and influence its function is limited. Here, we show that
α-actinin, which links membrane proteins to the actin cytoskeleton,
associates with ASIC1a in brain and in cultured cells. The interaction
depended on an α-actinin-binding site in the ASIC1a C terminus that was
specific for ASIC1a versus other ASICs and for α-actinin-1 and
-4. Co-expressing α-actinin-4 altered ASIC1a current density, pH
sensitivity, desensitization rate, and recovery from desensitization.
Moreover, reducing α-actinin expression altered acid-activated currents
in hippocampal neurons. These findings suggest that α-actinins may link
ASIC1a to a macromolecular complex in the postsynaptic membrane where it
regulates ASIC1a activity.Acid-sensing ion channels
(ASICs)2 are
H+-gated members of the DEG/ENaC family
(1–3).
Members of this family contain cytosolic N and C termini, two transmembrane
domains, and a large cysteine-rich extracellular domain. ASIC subunits combine
as homo- or heterotrimers to form cation channels that are widely expressed in
the central and peripheral nervous systems
(1–4).
In mammals, four genes encode ASICs, and two subunits, ASIC1 and ASIC2, have
two splice forms, a and b. Central nervous system neurons express ASIC1a,
ASIC2a, and ASIC2b
(5–7).
Homomeric ASIC1a channels are activated when extracellular pH drops below 7.2,
and half-maximal activation occurs at pH 6.5–6.8
(8–10).
These channels desensitize in the continued presence of a low extracellular
pH, and they can conduct Ca2+
(9,
11–13).
ASIC1a is required for acid-evoked currents in central nervous system neurons;
disrupting the gene encoding ASIC1a eliminates H+-gated currents
unless extracellular pH is reduced below pH 5.0
(5,
7).Previous studies found ASIC1a enriched in synaptosomal membrane fractions
and present in dendritic spines, the site of excitatory synapses
(5,
14,
15). Consistent with this
localization, ASIC1a null mice manifested deficits in hippocampal
long term potentiation, learning, and memory, which suggested that ASIC1a is
required for normal synaptic plasticity
(5,
16). ASICs might be activated
during neurotransmission when synaptic vesicles empty their acidic contents
into the synaptic cleft or when neuronal activity lowers extracellular pH
(17–19).
Ion channels, including those at the synapse often interact with multiple
proteins in a macromolecular complex that incorporates regulators of their
function (20,
21). For ASIC1a, only a few
interacting proteins have been identified. Earlier work indicated that ASIC1a
interacts with another postsynaptic scaffolding protein, PICK1
(15,
22,
23). ASIC1a also has been
reported to interact with annexin II light chain p11 through its cytosolic N
terminus to increase cell surface expression
(24) and with
Ca2+/calmodulin-dependent protein kinase II to phosphorylate the
channel (25). However, whether
ASIC1a interacts with additional proteins and with the cytoskeleton remain
unknown. Moreover, it is not known whether such interactions alter ASIC1a
function.In analyzing the ASIC1a amino acid sequence, we identified cytosolic
residues that might bind α-actinins. α-Actinins cluster membrane
proteins and signaling molecules into macromolecular complexes and link
membrane proteins to the actincytoskeleton (for review, Ref.
26). Four genes encode
α-actinin-1, -2, -3, and -4 isoforms. α-Actinins contain an
N-terminal head domain that binds F-actin, a C-terminal region containing two
EF-hand motifs, and a central rod domain containing four spectrin-like motifs
(26–28).
The C-terminal portion of the rod segment appears to be crucial for binding to
membrane proteins. The α-actinins assemble into antiparallel homodimers
through interactions in their rod domain. α-Actinins-1, -2, and -4 are
enriched in dendritic spines, concentrating at the postsynaptic membrane
(29–35).
In the postsynaptic membrane of excitatory synapses, α-actinin connects
the NMDA receptor to the actin cytoskeleton, and this interaction is key for
Ca2+-dependent inhibition of NMDA receptors
(36–38).
α-Actinins can also regulate the membrane trafficking and function of
several cation channels, including L-type Ca2+ channels,
K+ channels, and TRP channels
(39–41).To better understand the function of ASIC1a channels in macromolecular
complexes, we asked if ASIC1a associates with α-actinins. We were
interested in the α-actinins because they and ASIC1a, both, are present
in dendritic spines, ASIC1a contains a potential α-actinin binding
sequence, and the related epithelial Na+ channel (ENaC) interacts
with the cytoskeleton (42,
43). Therefore, we
hypothesized that α-actinin interacts structurally and functionally with
ASIC1a. 相似文献
2.
Philip D. Townsend Phillip M. Holliday Stepan Fenyk Kenneth C. Hess Michael A. Gray David R. W. Hodgson Martin J. Cann 《The Journal of biological chemistry》2009,284(2):784-791
Carbon dioxide is fundamental to the physiology of all organisms. There is
considerable interest in the precise molecular mechanisms that organisms use
to directly sense CO2. Here we demonstrate that a mammalian
recombinant G-protein-activated adenylyl cyclase and the related Rv1625c
adenylyl cyclase of Mycobacterium tuberculosis are specifically
stimulated by CO2. Stimulation occurred at physiological
concentrations of CO2 through increased kcat.
CO2 increased the affinity of enzyme for metal co-factor, but
contact with metal was not necessary as CO2 interacted directly
with apoenzyme. CO2 stimulated the activity of both
G-protein-regulated adenylyl cyclases and Rv1625c in vivo. Activation
of G-protein regulated adenylyl cyclases by CO2 gave a
corresponding increase in cAMP-response element-binding protein (CREB)
phosphorylation. Comparison of the responses of the G-protein regulated
adenylyl cyclases and the molecularly, and biochemically distinct mammalian
soluble adenylyl cyclase revealed that whereas G-protein-regulated enzymes are
responsive to CO2, the soluble adenylyl cyclase is responsive to
both CO2 and bicarbonate ion. We have, thus, identified a signaling
enzyme by which eukaryotes can directly detect and respond to fluctuating
CO2.Inorganic carbon
(Ci)3 is
central to prokaryotic and eukaryotic physiology. The predominant biologically
active forms of Ci are CO2 and
and their relative contributions
to the total Ci pool are pH-dependent. Biological roles for
CO2 and include
photosynthetic carbon fixation
(1), pH homeostasis
(2), carbon metabolism
(3), activation of virulence in
pathogenic organisms (4), sperm
maturation (5), and as an
alarmone in Drosophila
(6,
7).Given its importance in biology, the identification of CO2
responsive signaling pathways is key to understanding how organisms cope with
fluctuating CO2. Two seven transmembrane receptors, Gr21a and
Gr63a, have been shown to confer CO2 responsiveness in
Drosophila neurons (6,
7). Guanylyl cyclase D
expressing olfactory neurons also mediate sensitivity to CO2 in
mice (8). A role for
cGMP-activated channels in CO2 sensing has been observed in
CO2 avoidance behavior in Caenorhabditis
(9,
10). Despite these impressive
advances, no eukaryotic signaling enzymes unequivocally demonstrated to
respond to CO2 have been identified.The mammalian soluble adenylyl cyclase (sAC) synthesizes the second
messenger 3′,5′-cAMP and is directly stimulated by
(11–13).
Stimulation of sAC by has an
unequivocal role in sperm maturation
(5,
14–16).
sAC is a member of the Class III family of adenylyl cyclases (ACs), a family
that also includes the G-protein-regulated ACs and many examples from
prokaryotic genomes (17,
18). The Class III ACs can be
divided into four subclasses (a–d) based upon polymorphisms within the
active site (19). sAC is a
member of Class IIIb, a subclass characterized partly by replacement of a
substrate binding Asp with Thr. The Class IIIa ACs include the mammalian
G-protein-stimulated ACs and numerous prokaryotic examples. These have been
previously assumed to be non-responsive to Ci
(12).All prokaryotic Class IIIb ACs examined to date respond to Ci
including enzymes from organisms as diverse as Anabaena PCC 7120,
Mycobacterium tuberculosis, Stigmatella aurantiaca, and
Chloroflexus aurantiacus
(20,
21). Two Class IIIb ACs,
Slr1991 of Synechocystis PCC 6803 and CyaB1 of Anabaena PCC
7120, have been proven to respond to CO2 and not
, giving rise to the idea of AC as
a true gas-sensing molecule
(22,
23). The finding that Class
IIIb ACs respond to CO2 and not
necessitates an examination of the
assumption that G-protein-regulated ACs and related prokaryotic enzymes do not
respond to Ci.Here we demonstrate, contrary to previous work, that a recombinant
G-protein-regulated AC and the Class IIIa Rv1625c AC of M.
tuberculosis H37Rv show a pH-dependent response to Ci due to
specific stimulation by CO2 at physiologically relevant
concentrations. CO2 interacted directly with the apoprotein and
modulated the activity of both the prokaryotic enzyme and G-protein-regulated
AC in vivo. Finally, we contrasted the responses of sAC- and
G-protein-regulated ACs to different species of Ci and propose that
the mammalian cAMP signaling pathway is able to discriminate between
CO2 and in
vivo. 相似文献
3.
Lei Zhang Hui Zhao Yu Qiu Horace H. Loh Ping-Yee Law 《The Journal of biological chemistry》2009,284(4):1990-2000
Recent studies have revealed that in G protein-coupled receptor signalings
switching between G protein- and β-arrestin (βArr)-dependent
pathways occurs. In the case of opioid receptors, the signal is switched from
the initial inhibition of adenylyl cyclase (AC) to an increase in AC activity
(AC activation) during prolonged agonist treatment. The mechanism of such AC
activation has been suggested to involve the switching of G proteins activated
by the receptor, phosphorylation of signaling molecules, or receptor-dependent
recruitment of cellular proteins. Using protein kinase inhibitors, dominant
negative mutant studies and mouse embryonic fibroblast cells isolated from Src
kinase knock-out mice, we demonstrated that μ-opioid receptor
(OPRM1)-mediated AC activation requires direct association and activation of
Src kinase by lipid raft-located OPRM1. Such Src activation was independent of
βArr as indicated by the ability of OPRM1 to activate Src and AC after
prolonged agonist treatment in mouse embryonic fibroblast cells lacking both
βArr-1 and -2. Instead the switching of OPRM1 signals was dependent on
the heterotrimeric G protein, specifically Gi2 α-subunit.
Among the Src kinase substrates, OPRM1 was phosphorylated at Tyr336
within NPXXY motif by Src during AC activation. Mutation of this Tyr
residue, together with mutation of Tyr166 within the DRY motif to
Phe, resulted in the complete blunting of AC activation. Thus, the recruitment
and activation of Src kinase by OPRM1 during chronic agonist treatment, which
eventually results in the receptor tyrosine phosphorylation, is the key for
switching the opioid receptor signals from its initial AC inhibition to
subsequent AC activation.Classical G protein-coupled receptor
(GPCR)2 signaling
involves the activation of specific heterotrimeric G proteins and the
subsequent dissociation of α- and βγ-subunits. These G
protein subunits serve as the activators and/or inhibitors of several effector
systems, including adenylyl cyclases, phospholipases, and ion channels
(1). However, recent studies
have shown that GPCR signaling deviates from such a classical linear model.
For example, in kidney and colonic epithelial cells, protease-activated
receptor 1 can transduce its signals through either Gαi/o or
Gαq subunits via inhibition of small GTPase RhoA or
activation of RhoD. Thus, RhoA and RhoD act as molecular switches between the
negative and positive signaling activity of protease-activated receptor 1
(2). Another example is the
ability of β2-adrenergic receptor to switch from
Gs-dependent pathways to non-classical signaling pathways by
coupling to pertussis toxin-sensitive Gi proteins in a
cAMP-dependent protein kinase/protein kinase C phosphorylation-dependent
manner. In this case, the phosphorylation-induced switch in G protein coupling
provides the receptor access to alternative signaling pathways. For
β2-adrenergic receptors, this leads to a
Gi-dependent activation of MAP kinase
(3,
4). Furthermore the involvement
of protein scaffolds, such as β-arrestins in the MAP kinase cascade,
could also alter the GPCR signaling
(5–8).
Hence the formation of “signaling units” or
“receptosomes” would influence the GPCR signaling process and
destination.For opioid receptors, which are members of the rhodopsin GPCR subfamily
receptors, signal switching is also observed. Normally opioid receptors
inhibit AC activity, activate the MAP kinases and Kir3 K+ channels,
inhibit the voltage-dependent Ca2+ channels, and regulate other
effectors such as phospholipase C
(9). However, during prolonged
agonist treatment, not only is there a blunting of these cellular responses
but also a compensatory increase in intracellular cAMP level, which is
particularly significant upon the removal of the agonist or the addition of an
antagonist such as naloxone
(10–12).
This compensatory adenylyl cyclase activation phenomenon has been postulated
to be responsible for the development of drug tolerance and dependence
(13). The observed change from
receptor-mediated AC inhibition to receptor-mediated AC activation reflects
possible receptor signal switching. Although the exact mechanism for such
signal changes has yet to be elucidated, activation of specific protein
kinases and subsequent phosphorylation of AC isoforms
(14,
15) and other signaling
molecules (16) have been
suggested to be the key for observed AC activation. Among all the protein
kinases studied, involvement of protein kinase C, MAP kinase, and Raf-1 has
been implicated in the activation of AC
(17–19).
Alternative mechanisms, such as agonist-induced receptor internalization and
the increase in the constitutive activities of the receptor, also have been
suggested to play a role in increased AC activity after prolonged opioid
agonist treatment (20).
Earlier studies also implicated the switching of the opioid receptor from
Gi/Go to Gs coupling during chronic agonist
treatment (21). Regardless of
the mechanism, the exact molecular events that lead to the switching of opioid
receptor from an inhibitory response to a stimulatory response remain
elusive.Src kinases, which are members of the nonreceptor tyrosine kinase family,
have been implicated in GPCR function because several Src family members such
as cSrc, Fyn, and Yes have been reported to be activated by several GPCRs,
including β2-
(22) and β3
(23)-adrenergic,
M2- (24) and
M3 (25)-muscarinic,
and bradykinin receptors (26).
The GPCRs that are capable of activating Src predominantly couple to
Gi/o family G proteins
(27). Src kinases appear to
associate with, and be activated by, GPCRs themselves either through direct
interaction with intracellular receptor domains or by binding to
GPCR-associated proteins, such as G protein subunits or β-arrestins
(27). Src kinase has been
reported to be activated by κ-
(28) and δ
(29)-opioid receptors and
regulate the c-Jun kinase and MAP kinase activities. Src kinase within the
nucleus accumbens has been implicated in the rewarding effect and
hyperlocomotion induced by morphine in mice
(30). However, it is not clear
whether the Src kinase is activated and involved in the signal transduction in
AC activation after chronic opioid agonist administration.Previously we reported that the lipid raft location of the receptor and the
Gαi2 proteins are two prerequisites for the observed increase
in AC activity during prolonged agonist treatment
(31,
32). Because various protein
kinases including Src kinases and G proteins have been shown to be enriched in
lipid rafts (33), the roles of
these cellular proteins in the eventual switching of opioid receptor signals
from inhibition to stimulation of AC activity were examined in the current
studies. We were able to demonstrate that the association with and subsequent
activation of Src kinase by the μ-opioid receptor (OPRM1), which leads to
eventual tyrosine phosphorylation of OPRM1, are the cellular events required
for the switching of opioid receptor signaling upon chronic agonist
treatment. 相似文献
4.
5.
Jacamo R Sinnett-Smith J Rey O Waldron RT Rozengurt E 《The Journal of biological chemistry》2008,283(19):12877-12887
Protein kinase D (PKD) is a serine/threonine protein kinase rapidly
activated by G protein-coupled receptor (GPCR) agonists via a protein kinase C
(PKC)-dependent pathway. Recently, PKD has been implicated in the regulation
of long term cellular activities, but little is known about the mechanism(s)
of sustained PKD activation. Here, we show that cell treatment with the
preferential PKC inhibitors GF 109203X or Gö 6983 blocked rapid
(1–5-min) PKD activation induced by bombesin stimulation, but this
inhibition was greatly diminished at later times of bombesin stimulation
(e.g. 45 min). These results imply that GPCR-induced PKD activation
is mediated by early PKC-dependent and late PKC-independent mechanisms.
Western blot analysis with site-specific antibodies that detect the
phosphorylated state of the activation loop residues Ser744 and
Ser748 revealed striking PKC-independent phosphorylation of
Ser748 as well as Ser744 phosphorylation that remained
predominantly but not completely PKC-dependent at later times of bombesin or
vasopressin stimulation (20–90 min). To determine the mechanisms
involved, we examined activation loop phosphorylation in a set of PKD mutants,
including kinase-deficient, constitutively activated, and PKD forms in which
the activation loop residues were substituted for alanine. Our results show
that PKC-dependent phosphorylation of the activation loop Ser744
and Ser748 is the primary mechanism involved in early phase PKD
activation, whereas PKD autophosphorylation on Ser748 is a major
mechanism contributing to the late phase of PKD activation occurring in cells
stimulated by GPCR agonists. The present studies identify a novel mechanism
induced by GPCR activation that leads to late, PKC-independent PKD
activation.A rapid increase in the synthesis of lipid-derived second messengers with
subsequent activation of protein phosphorylation cascades has emerged as a
fundamental signal transduction mechanism triggered by multiple extracellular
stimuli, including hormones, neurotransmitters, chemokines, and growth factors
(1). Many of these agonists
bind to G protein-coupled receptors
(GPCRs),4 activate
heterotrimeric G proteins and stimulate isoforms of the phospholipase C
family, including β, γ, δ, and ε (reviewed in Refs.
1 and
2). Activated phospholipase Cs
catalyze the hydrolysis of phosphatidylinositol 4,5-bisphosphate to produce
the second messengers inositol 1,4,5-trisphosphate and diacylglycerol (DAG).
Inositol 1,4,5-trisphosphate mobilizes Ca2+ from intracellular
stores (3,
4) whereas DAG directly
activates the classic (α, β, and γ) and novel (δ,
ε, η, and θ) isoforms of PKC
(5–7).
Although it is increasingly recognized that each PKC isozyme has specific
functions in vivo
(5–8),
the mechanisms by which PKC-mediated signals are propagated to critical
downstream targets remain incompletely defined.PKD, also known initially as PKCμ
(9,
10), and two recently
identified serine protein kinases termed PKD2
(11) and PKCν/PKD3
(12,
13), which are similar in
overall structure and primary amino acid sequence to PKD
(14), constitute a new protein
kinase family within the Ca2+/calmodulin-dependent protein kinase
group (15) and separate from
the previously identified PKCs
(14). Salient features of PKD
structure include an N-terminal regulatory region containing a tandem repeat
of cysteine-rich zinc finger-like motifs (termed the cysteine-rich domain)
that confers high affinity binding to phorbol esters and DAG
(9,
16,
17), followed by a pleckstrin
homology (PH) domain that negatively regulates catalytic activity
(18,
19). The C-terminal region of
the PKDs contains its catalytic domain, which is distantly related to
Ca2+-regulated kinases.In unstimulated cells, PKD is in a state of low kinase catalytic activity
maintained by the N-terminal domain, which represses the catalytic activity of
the enzyme by autoinhibition. Consistent with this model, deletions or single
amino acid substitutions in the PH domain result in constitutive kinase
activity
(18–20).
Physiological activation of PKD within cells occurs via a
phosphorylation-dependent mechanism first identified in our laboratory
(21). In response to cellular
stimuli, PKD is converted from a low activity form into a persistently active
form that is retained during isolation from cells, as shown by in
vitro kinase assays performed in the absence of lipid co-activators
(21,
22). PKD activation has been
demonstrated in response to engagement of specific GPCRs either by regulatory
peptides
(23–30)
or lysophosphatidic acid (27,
31,
32); signaling through
Gq, G12, Gi, and Rho
(27,
31–34);
activation of receptor tyrosine kinases, such as the platelet-derived growth
factor receptor (23,
35,
36); cross-linking of B-cell
receptor and T-cell receptor in B and T lymphocytes, respectively
(37–40);
and oxidative stress
(41–44).Throughout these studies, multiple lines of evidence indicated that PKC
activity is necessary for rapid PKD activation within intact cells. For
example, rapid PKD activation was selectively and potently blocked by cell
treatment with preferential PKC inhibitors (e.g. GF 109203X or
Gö 6983) that do not directly inhibit PKD catalytic activity
(21,
22), implying that PKD
activation in intact cells is mediated, directly or indirectly, through PKCs.
In line with this conclusion, cotransfection of PKD with active mutant forms
of “novel” PKCs (PKCs δ, ε, η, and θ)
resulted in robust PKD activation in the absence of cell stimulation
(21,
44–46).
Many reports demonstrated the operation of a rapid PKC/PKD signaling cascade
in response to multiple GPCR agonists in a broad range of cell types,
including normal and cancer cells (reviewed in Ref.
14). Our previous studies
identified Ser744 and Ser748 in the PKD activation loop
(also referred as the activation segment or T-loop) as phosphorylation sites
critical for PKC-mediated PKD activation (reviewed in Ref.
14). Collectively, these
findings demonstrated the existence of rapidly activated PKC-PKD protein
kinase cascade(s) and raised the possibility that some PKC-dependent
biological responses involve PKD acting as a downstream effector.PKD has been reported recently to mediate several important cellular
activities and processes, including signal transduction
(30,
47–49),
chromatin modification (50),
Golgi organization and function
(51,
52), c-Jun function
(47,
53,
54), NFκB-mediated gene
expression (43,
55,
56), and cell survival,
migration, and differentiation and DNA synthesis and proliferation (reviewed
in Ref. 14). Thus, mounting
evidence indicates that PKD has a remarkable diversity of both its signal
generation and distribution and its potential for complex regulatory
interactions with multiple downstream pathways, leading to multiple responses,
including long term cellular events. Despite increasing recognition of its
importance, very little is known about the mechanism(s) of sustained PKD
activation as opposed to the well documented rapid, PKC-dependent PKD
activation.The results presented here demonstrate that prolonged GPCR-induced PKD
activation is mediated by sequential PKC-dependent and PKC-independent phases
of regulation. We report here, for the first time, that PKD
autophosphorylation on Ser748 is a major mechanism contributing to
the late phase of PKD activation occurring in cells stimulated by GPCR
agonists. The present studies expand previous models of PKD regulation by
identifying a novel mechanism induced by GPCR activation that leads to late,
PKC-independent PKD activation. 相似文献
6.
7.
Lilly Y. W. Bourguignon Weiliang Xia Gabriel Wong 《The Journal of biological chemistry》2009,284(5):2657-2671
8.
The inhalation anesthetic desflurane induces caspase activation and increases amyloid beta-protein levels under hypoxic conditions 总被引:1,自引:0,他引:1
Zhang B Dong Y Zhang G Moir RD Xia W Yue Y Tian M Culley DJ Crosby G Tanzi RE Xie Z 《The Journal of biological chemistry》2008,283(18):11866-11875
Perioperative factors including hypoxia, hypocapnia, and certain
anesthetics have been suggested to contribute to Alzheimer disease (AD)
neuropathogenesis. Desflurane is one of the most commonly used inhalation
anesthetics. However, the effects of desflurane on AD neuropathogenesis have
not been previously determined. Here, we set out to assess the effects of
desflurane and hypoxia on caspase activation, amyloid precursor protein (APP)
processing, and amyloid β-protein (Aβ) generation in H4 human
neuroglioma cells (H4 naïve cells) as well as those overexpressing APP
(H4-APP cells). Neither 12% desflurane nor hypoxia (18% O2) alone
affected caspase-3 activation, APP processing, and Aβ generation.
However, treatment with a combination of 12% desflurane and hypoxia (18%
O2) (desflurane/hypoxia) for 6 h induced caspase-3 activation,
altered APP processing, and increased Aβ generation in H4-APP cells.
Desflurane/hypoxia also increased levels of β-site APP-cleaving enzyme in
H4-APP cells. In addition, desflurane/hypoxia-induced Aβ generation could
be reduced by the broad caspase inhibitor benzyloxycarbonyl-VAD. Finally, the
Aβ aggregation inhibitor clioquinol and γ-secretase inhibitor
L-685,458 attenuated caspase-3 activation induced by desflurane/hypoxia. In
summary, desflurane can induce Aβ production and caspase activation, but
only in the presence of hypoxia. Pending in vivo confirmation, these
data may have profound implications for anesthesia care in elderly patients,
and especially those with AD.An estimated 200 million patients worldwide undergo surgery each year.
Several reports have suggested that anesthesia and surgery may facilitate
development of Alzheimer disease
(AD)4
(1–3).
A recent study also reported that patients having coronary artery bypass graft
surgery under general anesthesia are at increased risk for AD as compared with
those having percutaneous transluminal coronary angioplasty under local
anesthesia (4).Genetic evidence, confirmed by neuropathological and biochemical findings,
indicates that excessive production and/or accumulation of amyloid
β-protein (Aβ) play a fundamental role in the pathology of AD
(reviewed in Refs. 5 and
6). Aβ is produced via
serial proteolysis of amyloid precursor protein (APP) by aspartyl protease
β-site APP-cleaving enzyme (BACE), or β-secretase,
andγ-secretase. BACE cleaves APP to generate a 99-residue
membrane-associated C terminus fragment (APP-C99). APP-C99 is further cleaved
by γ-secretase to release 4-kDa Aβ and β-amyloid precursor
protein intracellular domain
(7–9).
Presenilin and γ-secretase co-fractionate as a detergent-sensitive, high
molecular weight complex (10)
that includes at least three other proteins, nicastrin/APH-2, APH-1, and
PEN-2, all of which are necessary and sufficient for γ-secretase
activity
(11–13).
Increasing evidence indicates that apoptosis is associated with a variety of
neurodegenerative disorders, including AD (Refs.
14–17;
reviewed in Ref. 18). Aβ
has been shown to cause caspase activation and apoptosis, which can in turn
potentiate Aβ generation
(16,
19–28).
Finally, fibrillar aggregates of Aβ and oligomeric species of Aβ are
more neurotoxic
(29–37).Perioperative factors, including hypoxia
(38–42),
hypocapnia (43), and
anesthetics
(44–47),
have been reported to potentially contribute to AD neuropathogenesis. These
perioperative factors may also cause post-operative cognitive dysfunction, a
dementia associated with surgery and anesthesia, by triggering AD
neuropathogenesis.Isoflurane, sevoflurane, and desflurane are the most commonly used
inhalation anesthetics. It has been reported that isoflurane enhances the
oligomerization and cytotoxicity of Aβ
(44) and induces apoptosis
(48–51).
Our recent studies have shown that a clinically relevant concentration of
isoflurane can lead to caspase-3 activation, decrease cell viability, alter
APP processing, and increase Aβ generation in human H4 neuroglioma cells
overexpressing human APP
(45–47).
Loop et al. (49)
reported that isoflurane and sevoflurane, but not desflurane, can induce
caspase activation and apoptosis in human T lymphocytes. However, effects of
desflurane and desflurane plus other perioperative risk factors, e.g.
hypoxia, on APP processing and Aβ generation have not been assessed.In the present study, we set out to determine effects of desflurane,
hypoxia, and the combination of the two (desflurane/hypoxia) on caspase-3
activation, APP processing, and Aβ generation in H4 human neuroglioma
cells (H4 naïve cells) and H4 naïve cells stably transfected to
express full-length (FL) APP (H4-APP cells). We also investigated whether the
caspase inhibitor, Z-VAD, the γ-secretase inhibitor L-685,458, and the
Aβ aggregation inhibitor clioquinol could attenuate
desflurane/hypoxia-induced caspase-3 activation and Aβ generation. 相似文献
9.
Omar Ramadan Yongxia Qu Raj Wadgaonkar Ghayath Baroudi Eddy Karnabi Mohamed Chahine Mohamed Boutjdir 《The Journal of biological chemistry》2009,284(8):5042-5049
The novel α1D L-type Ca2+ channel is expressed
in supraventricular tissue and has been implicated in the pacemaker activity
of the heart and in atrial fibrillation. We recently demonstrated that PKA
activation led to increased α1D Ca2+ channel
activity in tsA201 cells by phosphorylation of the channel protein. Here we
sought to identify the phosphorylated PKA consensus sites on the
α1 subunit of the α1D Ca2+
channel by generating GST fusion proteins of the intracellular loops, N
terminus, proximal and distal C termini of the α1 subunit of
α1D Ca2+ channel. An in vitro PKA kinase
assay was performed for the GST fusion proteins, and their phosphorylation was
assessed by Western blotting using either anti-PKA substrate or
anti-phosphoserine antibodies. Western blotting showed that the N terminus and
C terminus were phosphorylated. Serines 1743 and 1816, two PKA consensus
sites, were phosphorylated by PKA and identified by mass spectrometry. Site
directed mutagenesis and patch clamp studies revealed that serines 1743 and
1816 were major functional PKA consensus sites. Altogether, biochemical and
functional data revealed that serines 1743 and 1816 are major functional PKA
consensus sites on the α1 subunit of α1D
Ca2+ channel. These novel findings provide new insights into the
autonomic regulation of the α1D Ca2+ channel in
the heart.L-type Ca2+ channels are essential for the generation of normal
cardiac rhythm, for induction of rhythm propagation through the
atrioventricular node and for the contraction of the atrial and ventricular
muscles
(1–5).
L-type Ca2+ channel is a multisubunit complex including
α1, β and α2/δ subunits
(5–7).
The α1 subunit contains the voltage sensor, the selectivity
filter, the ion conduction pore, and the binding sites for all known
Ca2+ channel blockers
(6–9).
While α1C Ca2+ channel is expressed in the atria
and ventricles of the heart
(10–13),
expression of α1D Ca2+ channel is restricted to
the sinoatrial (SA)2
and atrioventricular (AV) nodes, as well as in the atria, but not in the adult
ventricles (2,
3,
10).Only recently it has been realized that α1D along with
α1C Ca2+ channels contribute to L-type
Ca2+ current (ICa-L) and they both play important but
unique roles in the physiology/pathophysiology of the heart
(6–9).
Compared with α1C, α1D L-type
Ca2+ channel activates at a more negative voltage range and shows
slower current inactivation during depolarization
(14,
15). These properties may
allow α1D Ca2+ channel to play critical roles in
SA and AV nodes function. Indeed, α1D Ca2+ channel
knock-out mice exhibit significant SA dysfunction and various degrees of AV
block (12,
16–19).The modulation of α1C Ca2+ channel by
cAMP-dependent PKA phosphorylation has been extensively studied, and the C
terminus of α1 was identified as the site of the modulation
(20–22).
Our group was the first to report that 8-bromo-cAMP (8-Br-cAMP), a
membrane-permeable cAMP analog, increased α1D Ca2+
channel activity using patch clamp studies
(2). However, very little is
known about potential PKA phosphorylation consensus motifs on the
α1D Ca2+ channel. We therefore hypothesized that
the C terminus of the α1 subunit of the α1D
Ca2+ channel mediates its modulation by cAMP-dependent PKA
pathway. 相似文献
10.
Benjamin E. L. Lauffer Stanford Chen Cristina Melero Tanja Kortemme Mark von Zastrow Gabriel A. Vargas 《The Journal of biological chemistry》2009,284(4):2448-2458
Many G protein-coupled receptors (GPCRs) recycle after agonist-induced
endocytosis by a sequence-dependent mechanism, which is distinct from default
membrane flow and remains poorly understood. Efficient recycling of the
β2-adrenergic receptor (β2AR) requires a C-terminal PDZ
(PSD-95/Discs Large/ZO-1) protein-binding determinant (PDZbd), an intact actin
cytoskeleton, and is regulated by the endosomal protein Hrs (hepatocyte growth
factor-regulated substrate). The PDZbd is thought to link receptors to actin
through a series of protein interaction modules present in NHERF/EBP50
(Na+/H+ exchanger 3 regulatory factor/ezrin-binding phosphoprotein
of 50 kDa) family and ERM (ezrin/radixin/moesin) family proteins. It is not
known, however, if such actin connectivity is sufficient to recapitulate the
natural features of sequence-dependent recycling. We addressed this question
using a receptor fusion approach based on the sufficiency of the PDZbd to
promote recycling when fused to a distinct GPCR, the δ-opioid receptor,
which normally recycles inefficiently in HEK293 cells. Modular domains
mediating actin connectivity promoted receptor recycling with similarly high
efficiency as the PDZbd itself, and recycling promoted by all of the domains
was actin-dependent. Regulation of receptor recycling by Hrs, however, was
conferred only by the PDZbd and not by downstream interaction modules. These
results suggest that actin connectivity is sufficient to mimic the core
recycling activity of a GPCR-linked PDZbd but not its cellular regulation.G protein-coupled receptors
(GPCRs)2 comprise the
largest family of transmembrane signaling receptors expressed in animals and
transduce a wide variety of physiological and pharmacological information.
While these receptors share a common 7-transmembrane-spanning topology,
structural differences between individual GPCR family members confer diverse
functional and regulatory properties
(1-4).
A fundamental mechanism of GPCR regulation involves agonist-induced
endocytosis of receptors via clathrin-coated pits
(4). Regulated endocytosis can
have multiple functional consequences, which are determined in part by the
specificity with which internalized receptors traffic via divergent downstream
membrane pathways
(5-7).Trafficking of internalized GPCRs to lysosomes, a major pathway traversed
by the δ-opioid receptor (δOR), contributes to proteolytic
down-regulation of receptor number and produces a prolonged attenuation of
subsequent cellular responsiveness to agonist
(8,
9). Trafficking of internalized
GPCRs via a rapid recycling pathway, a major route traversed by the
β2-adrenergic receptor (β2AR), restores the complement of functional
receptors present on the cell surface and promotes rapid recovery of cellular
signaling responsiveness (6,
10,
11). When co-expressed in the
same cells, the δOR and β2AR are efficiently sorted between these
divergent downstream membrane pathways, highlighting the occurrence of
specific molecular sorting of GPCRs after endocytosis
(12).Recycling of various integral membrane proteins can occur by default,
essentially by bulk membrane flow in the absence of lysosomal sorting
determinants (13). There is
increasing evidence that various GPCRs, such as the β2AR, require
distinct cytoplasmic determinants to recycle efficiently
(14). In addition to requiring
a cytoplasmic sorting determinant, sequence-dependent recycling of the
β2AR differs from default recycling in its dependence on an intact actin
cytoskeleton and its regulation by the conserved endosomal sorting protein Hrs
(hepatocyte growth factor receptor substrate)
(11,
14). Compared with the present
knowledge regarding protein complexes that mediate sorting of GPCRs to
lysosomes (15,
16), however, relatively
little is known about the biochemical basis of sequence-directed recycling or
its regulation.The β2AR-derived recycling sequence conforms to a canonical PDZ
(PSD-95/Discs Large/ZO-1) protein-binding determinant (henceforth called
PDZbd), and PDZ-mediated protein association(s) with this sequence appear to
be primarily responsible for its endocytic sorting activity
(17-20).
Fusion of this sequence to the cytoplasmic tail of the δOR effectively
re-routes endocytic trafficking of engineered receptors from lysosomal to
recycling pathways, establishing the sufficiency of the PDZbd to function as a
transplantable sorting determinant
(18). The β2AR-derived
PDZbd binds with relatively high specificity to the NHERF/EBP50 family of PDZ
proteins (21,
22). A well-established
biochemical function of NHERF/EBP50 family proteins is to associate integral
membrane proteins with actin-associated cytoskeletal elements. This is
achieved through a series of protein-interaction modules linking NHERF/EBP50
family proteins to ERM (ezrin-radixin-moesin) family proteins and, in turn, to
actin filaments
(23-26).
Such indirect actin connectivity is known to mediate other effects on plasma
membrane organization and function
(23), however, and NHERF/EBP50
family proteins can bind to additional proteins potentially important for
endocytic trafficking of receptors
(23,
25). Thus it remains unclear
if actin connectivity is itself sufficient to promote sequence-directed
recycling of GPCRs and, if so, if such connectivity recapitulates the normal
cellular regulation of sequence-dependent recycling. In the present study, we
took advantage of the modular nature of protein connectivity proposed to
mediate β2AR recycling
(24,
26), and extended the opioid
receptor fusion strategy used successfully for identifying diverse recycling
sequences in GPCRs
(27-29),
to address these fundamental questions.Here we show that the recycling activity of the β2AR-derived PDZbd can
be effectively bypassed by linking receptors to ERM family proteins in the
absence of the PDZbd itself. Further, we establish that the protein
connectivity network can be further simplified by fusing receptors to an
interaction module that binds directly to actin filaments. We found that
bypassing the PDZ-mediated interaction using either domain is sufficient to
mimic the ability of the PDZbd to promote efficient, actin-dependent recycling
of receptors. Hrs-dependent regulation, however, which is characteristic of
sequence-dependent recycling of wild-type receptors, was recapitulated only by
the fused PDZbd and not by the proposed downstream interaction modules. These
results support a relatively simple architecture of protein connectivity that
is sufficient to mimic the core recycling activity of the β2AR-derived
PDZbd, but not its characteristic cellular regulation. Given that an
increasing number of GPCRs have been shown to bind PDZ proteins that typically
link directly or indirectly to cytoskeletal elements
(17,
27,
30-32),
the present results also suggest that actin connectivity may represent a
common biochemical principle underlying sequence-dependent recycling of
various GPCRs. 相似文献
11.
12.
Yun Liu Yun-wu Zhang Xin Wang Han Zhang Xiaoqing You Francesca-Fang Liao Huaxi Xu 《The Journal of biological chemistry》2009,284(18):12145-12152
Excessive accumulation of β-amyloid peptides in the brain is a major
cause for the pathogenesis of Alzheimer disease. β-Amyloid is derived
from β-amyloid precursor protein (APP) through sequential cleavages by
β- and γ-secretases, whose enzymatic activities are tightly
controlled by subcellular localization. Delineation of how intracellular
trafficking of these secretases and APP is regulated is important for
understanding Alzheimer disease pathogenesis. Although APP trafficking is
regulated by multiple factors including presenilin 1 (PS1), a major component
of the γ-secretase complex, and phospholipase D1 (PLD1), a
phospholipid-modifying enzyme, regulation of intracellular trafficking of
PS1/γ-secretase and β-secretase is less clear. Here we demonstrate
that APP can reciprocally regulate PS1 trafficking; APP deficiency results in
faster transport of PS1 from the trans-Golgi network to the cell
surface and increased steady state levels of PS1 at the cell surface, which
can be reversed by restoring APP levels. Restoration of APP in APP-deficient
cells also reduces steady state levels of other γ-secretase components
(nicastrin, APH-1, and PEN-2) and the cleavage of Notch by
PS1/γ-secretase that is more highly correlated with cell surface levels
of PS1 than with APP overexpression levels, supporting the notion that Notch
is mainly cleaved at the cell surface. In contrast, intracellular trafficking
of β-secretase (BACE1) is not regulated by APP. Moreover, we find that
PLD1 also regulates PS1 trafficking and that PLD1 overexpression promotes cell
surface accumulation of PS1 in an APP-independent manner. Our results clearly
elucidate a physiological function of APP in regulating protein trafficking
and suggest that intracellular trafficking of PS1/γ-secretase is
regulated by multiple factors, including APP and PLD1.An important pathological hallmark of Alzheimer disease
(AD)4 is the formation
of senile plaques in the brains of patients. The major components of those
plaques are β-amyloid peptides (Aβ), whose accumulation triggers a
cascade of neurodegenerative steps ending in formation of senile plaques and
intraneuronal fibrillary tangles with subsequent neuronal loss in susceptible
brain regions (1,
2). Aβ is proteolytically
derived from the β-amyloid precursor protein (APP) through sequential
cleavages by β-secretase (BACE1), a novel membrane-bound aspartyl
protease (3,
4), and by γ-secretase, a
high molecular weight complex consisting of at least four components:
presenilin (PS), nicastrin (NCT), anterior pharynx-defective-1 (APH-1), and
presenilin enhancer-2 (PEN-2)
(5,
6). APP is a type I
transmembrane protein belonging to a protein family that includes APP-like
protein 1 (APLP1) and 2 (APLP2) in mammals
(7,
8). Full-length APP is
synthesized in the endoplasmic reticulum (ER) and transported through the
Golgi apparatus. Most secreted Aβ peptides are generated within the
trans-Golgi network (TGN), also the major site of steady state APP in
neurons
(9–11).
APP can be transported to the cell surface in TGN-derived secretory vesicles
if not proteolyzed to Aβ or an intermediate metabolite. At the cell
surface APP is either cleaved by α-secretase to produce soluble
sAPPα (12) or
reinternalized for endosomal/lysosomal degradation
(13,
14). Aβ may also be
generated in endosomal/lysosomal compartments
(15,
16). In contrast to neurotoxic
Aβ peptides, sAPPα possesses neuroprotective potential
(17,
18). Thus, the subcellular
distribution of APP and proteases that process it directly affect the ratio of
sAPPα to Aβ, making delineation of the mechanisms responsible for
regulating trafficking of all of these proteins relevant to AD
pathogenesis.Presenilin (PS) is a critical component of the γ-secretase. Of the
two mammalian PS gene homologues, PS1 and PS2, PS1
encodes the major form (PS1) in active γ-secretase
(19,
20). Nascent PSs undergo
endoproteolytic cleavage to generate an amino-terminal fragment (NTF) and a
carboxyl-terminal fragment (CTF) to form a functional PS heterodimer
(21). Based on observations
that PSs possess two highly conserved aspartate residues indispensable for
γ-secretase activity and that specific transition state analogue
γ-secretase inhibitors bind to PS1 NTF/CTF heterodimers
(5,
22), PSs are believed to be
the catalytic component of the γ-secretase complex. PS assembles with
three other components, NCT, APH-1, and PEN-2, to form the functional
γ-secretase (5,
6). Strong evidence suggests
that PS1/γ-secretase resides principally in the ER, early Golgi, TGN,
endocytic and intermediate compartments, most of which (except the TGN) are
not major subcellular sites for APP
(23,
24). In addition to generating
Aβ and cleaving APP to release the APP intracellular domain,
PS1/γ-secretase cleaves other substrates such as Notch
(25), cadherin
(26), ErbB4
(27), and CD44
(28), releasing their
respective intracellular domains. Interestingly, PS1/γ-secretase
cleavage of different substrates seems to occur at different subcellular
compartments; APP is mainly cleaved at the TGN and early endosome domains,
whereas Notch is predominantly cleaved at the cell surface
(9,
11,
29). Thus, perturbing
intracellular trafficking of PS1/γ-secretase may alter interactions
between PS1/γ-secretase and APP, contributing to either abnormal Aβ
generation and AD pathogenesis or decreased access of PS1/γ-secretase to
APP such that Aβ production is reduced. However, mechanisms regulating
PS1/γ-secretase trafficking warrant further investigation.In addition to participating in γ-secretase activity, PS1 regulates
intracellular trafficking of several membrane proteins, including other
γ-secretase components (nicastrin, APH-1, and PEN-2) and the substrate
APP (reviewed in Ref. 30).
Intracellular APP trafficking is highly regulated and requires other factors
such as mint family members and SorLA
(2). Moreover, we recently
found that phospholipase D1 (PLD1), a phospholipid-modifying enzyme that
regulates membrane trafficking events, can interact with PS1, and can regulate
budding of APP-containing vesicles from the TGN and delivery of APP to the
cell surface (31,
32). Interestingly, Kamal
et al. (33)
identified an axonal membrane compartment that contains APP, BACE1, and PS1
and showed that fast anterograde axonal transport of this compartment is
mediated by APP and kinesin-I, implying a traffic-regulating role for APP.
Increased APP expression is also shown to decrease retrograde axonal transport
of nerve growth factor (34).
However, whether APP indeed regulates intracellular trafficking of proteins
including BACE1 and PS1/γ-secretase requires further validation. In the
present study we demonstrate that intracellular trafficking of PS1, as well as
that of other γ-secretase components, but not BACE1, is regulated by
APP. APP deficiency promotes cell surface delivery of PS1/γ-secretase
complex and facilitates PS1/γ-secretase-mediated Notch cleavage. In
addition, we find that PLD1 also regulates intracellular trafficking of PS1
through a different mechanism and more potently than APP. 相似文献
13.
Christian Rosker Gargi Meur Emily J. A. Taylor Colin W. Taylor 《The Journal of biological chemistry》2009,284(8):5186-5194
Ryanodine receptors (RyR) are Ca2+ channels that mediate
Ca2+ release from intracellular stores in response to diverse
intracellular signals. In RINm5F insulinoma cells, caffeine, and
4-chloro-m-cresol (4CmC), agonists of RyR, stimulated Ca2+
entry that was independent of store-operated Ca2+ entry, and
blocked by prior incubation with a concentration of ryanodine that inactivates
RyR. Patch-clamp recording identified small numbers of large-conductance
(γK = 169 pS) cation channels that were activated by
caffeine, 4CmC or low concentrations of ryanodine. Similar channels were
detected in rat pancreatic β-cells. In RINm5F cells, the channels were
blocked by cytosolic, but not extracellular, ruthenium red. Subcellular
fractionation showed that type 3 IP3 receptors (IP3R3)
were expressed predominantly in endoplasmic reticulum, whereas RyR2 were
present also in plasma membrane fractions. Using RNAi selectively to reduce
expression of RyR1, RyR2, or IP3R3, we showed that RyR2 mediates
both the Ca2+ entry and the plasma membrane currents evoked by
agonists of RyR. We conclude that small numbers of RyR2 are selectively
expressed in the plasma membrane of RINm5F pancreatic β-cells, where they
mediate Ca2+ entry.Ryanodine receptors
(RyR)3 and inositol
1,4,5-trisphosphate receptors (IP3R)
(1,
2) are the archetypal
intracellular Ca2+ channels. Both are widely expressed, although
RyR are more restricted in their expression than IP3R
(3,
4). In common with many cells,
pancreatic β-cells and insulin-secreting cell lines express both
IP3R (predominantly IP3R3)
(5,
6) and RyR (predominantly RyR2)
(7). Both RyR and
IP3R are expressed mostly within membranes of the endoplasmic (ER),
where they mediate release of Ca2+. Functional RyR are also
expressed in the secretory vesicles
(8,
9) or, and perhaps more likely,
in the endosomes of β-cells
(10). Despite earlier
suggestions (11),
IP3R are probably not present in the secretory vesicles of
β-cells (8,
12,
13).All three subtypes of IP3R are stimulated by IP3 with
Ca2+ (1), and the
three subtypes of RyR are each directly regulated by Ca2+. However,
RyR differ in whether their most important physiological stimulus is
depolarization of the plasma membrane (RyR1), Ca2+ (RyR2) or
additional intracellular messengers like cyclic ADP-ribose. The latter
stimulates both Ca2+ release and insulin secretion in β-cells
(8,
14). The activities of both
families of intracellular Ca2+ channels are also modulated by many
additional signals that act directly or via phosphorylation
(15,
16). Although they commonly
mediate release of Ca2+ from the ER, both IP3R and RyR
select rather poorly between Ca2+ and other cations (permeability
ratio, PCa/PK ∼7)
(1,
17). This may allow
electrogenic Ca2+ release from the ER to be rapidly compensated by
uptake of K+ (18),
and where RyR or IP3R are expressed in other membranes it may allow
them to affect membrane potential.Both Ca2+ entry and release of Ca2+ from
intracellular stores contribute to the oscillatory increases in cytosolic
Ca2+ concentration ([Ca2+]i) that
stimulate exocytosis of insulin-containing vesicles in pancreatic β-cells
(7). Glucose rapidly
equilibrates across the plasma membrane (PM) of β-cells and its oxidative
metabolism by mitochondria increases the cytosolic ATP/ADP ratio, causing
KATP channels to close
(19). This allows an
unidentified leak current to depolarize the PM
(20) and activate
voltage-gated Ca2+ channels, predominantly L-type Ca2+
channels (21). The resulting
Ca2+ entry is amplified by Ca2+-induced Ca2+
release from intracellular stores
(7), triggering exocytotic
release of insulin-containing dense-core vesicles
(22). The importance of this
sequence is clear from the widespread use of sulfonylurea drugs, which close
KATP channels, in the treatment of type 2 diabetes. Ca2+
uptake by mitochondria beneath the PM further stimulates ATP production,
amplifying the initial response to glucose and perhaps thereby contributing to
the sustained phase of insulin release
(23). However, neither the
increase in [Ca2+]i nor the insulin release
evoked by glucose or other nutrients is entirely dependent on Ca2+
entry (7,
24) or closure of
KATP channels (25).
This suggests that glucose metabolism may also more directly activate RyR
(7,
26) and/or IP3R
(27) to cause release of
Ca2+ from intracellular stores. A change in the ATP/ADP ratio is
one means whereby nutrient metabolism may be linked to opening of
intracellular Ca2+ channels because both RyR
(28) and IP3R
(1) are stimulated by ATP.The other major physiological regulators of insulin release are the
incretins: glucagon-like peptide-1 and glucose-dependent insulinotropic
hormone (29). These hormones,
released by cells in the small intestine, stimulate synthesis of cAMP in
β-cells and thereby potentiate glucose-evoked insulin release
(30). These pathways are also
targets of drugs used successfully to treat type 2 diabetes
(29). The responses of
β-cells to cAMP involve both cAMP-dependent protein kinase and epacs
(exchange factors activated by cAMP)
(31,
32). The effects of the latter
are, at least partly, due to release of Ca2+ from intracellular
stores via RyR
(33–35)
and perhaps also via IP3R
(36). The interplays between
Ca2+ and cAMP signaling generate oscillatory changes in the
concentrations of both messengers
(37). RyR and IP3R
are thus implicated in mediating responses to each of the major physiological
regulators of insulin secretion: glucose and incretins.Here we report that in addition to expression in intracellular stores,
which probably include both the ER and secretory vesicles and/or endosomes,
functional RyR2 are also expressed in small numbers in the PM of RINm5F
insulinoma cells and rat pancreatic β-cells. 相似文献
14.
Control of TANK-binding Kinase 1-mediated Signaling by the
��134.5 Protein of Herpes Simplex Virus
1
Dustin Verpooten Yijie Ma Songwang Hou Zhipeng Yan Bin He 《The Journal of biological chemistry》2009,284(2):1097-1105
TANK-binding kinase 1 (TBK1) is a key component of Toll-like
receptor-dependent and -independent signaling pathways. In response to
microbial components, TBK1 activates interferon regulatory factor 3 (IRF3) and
cytokine expression. Here we show that TBK1 is a novel target of the
γ134.5 protein, a virulence factor whose expression is
regulated in a temporal fashion. Remarkably, the γ134.5
protein is required to inhibit IRF3 phosphorylation, nuclear translocation,
and the induction of antiviral genes in infected cells. When expressed in
mammalian cells, the γ134.5 protein forms complexes with TBK1
and disrupts the interaction of TBK1 and IRF3, which prevents the induction of
interferon and interferon-stimulated gene promoters. Down-regulation of TBK1
requires the amino-terminal domain. In addition, unlike wild type virus, a
herpes simplex virus mutant lacking γ134.5 replicates
efficiently in TBK1-/- cells but not in TBK1+/+ cells.
Addition of exogenous interferon restores the antiviral activity in both
TBK1-/- and TBK+/+ cells. Hence, control of
TBK1-mediated cell signaling by the γ134.5 protein
contributes to herpes simplex virus infection. These results reveal that TBK1
plays a pivotal role in limiting replication of a DNA virus.Herpes simplex virus 1
(HSV-1)3 is a large
DNA virus that establishes latent or lytic infection, in which the virus
triggers innate immune responses. In HSV-infected cells, a number of antiviral
mechanisms operate in a cell type- and time-dependent manner
(1). In response to
double-stranded RNA (dsRNA), Toll-like receptor 3 (TLR3) recruits an adaptor
TIR domain-containing adaptor inducing IFN-β and stimulates cytokine
expression (2,
3). In the cytoplasm, RNA
helicases, RIG-I (retinoid acid-inducible gene-I), and MDA5 (melanoma
differentiation associated gene 5) recognize intracellular viral
5′-triphosphate RNA or dsRNA
(2,
4). Furthermore, a
DNA-dependent activator of IFN-regulatory factor (DAI) senses double-stranded
DNA in the cytoplasm and induces cytokine expression
(5). There is also evidence
that viral entry induces antiviral programs independent of TLR and RIG-I
pathways (6). While recognizing
distinct viral components, these innate immune pathways relay signals to the
two IKK-related kinases, TANK-binding kinase 1 (TBK1) and inducible IκB
kinase (IKKi) (2).The IKK-related kinases function as essential components that phosphorylate
IRF3 (interferon regulatory factor 3), as well as the closely related IRF7,
which translocates to the nucleus and induces antiviral genes, such as
interferon-α/β and ISG56 (interferon-stimulated gene 56)
(7,
8). TBK1 is constitutively
expressed, whereas IKKi is engaged as an inducible gene product of innate
immune signaling (9,
10). IRF3 activation is
attenuated in TBK1-deficient but not in IKKi-deficient cells
(11,
12). Its activation is
completely abolished in double-deficient cells
(12), suggesting a partially
redundant function of TBK1 and IKKi. Indeed, IKKi also negatively regulates
the STAT-signaling pathway
(13). TBK1/IKKi interacts with
several proteins, such as TRAF family member-associated NF-κB activator
(TANK), NAP1 (NAK-associated protein 1), similar to NAP1TBK1 adaptor
(SINTBAD), DNA-dependent activator of IFN-regulatory factors (DAI), and
secretory protein 5 (Sec5) in host cells
(5,
14–18).
These interactions are thought to regulate TBK1/IKKi, which delineates innate
as well as adaptive immune responses.Upon viral infection, expression of HSV proteins interferes with the
induction of antiviral immunity. When treated with UV or cycloheximide, HSV
induces an array of antiviral genes in human lung fibroblasts
(19,
20). Furthermore, an HSV
mutant, with deletion in immediate early protein ICP0, induces ISG56
expression (21). Accordingly,
expression of ICP0 inhibits the induction of antiviral programs mediated by
IRF3 or IRF7
(21–23).
However, although ICP0 negatively regulates IFN-β expression, it is not
essential for this effect
(24). In HSV-infected human
macrophages or dendritic cells, an immediate early protein ICP27 is required
to suppress cytokine induction involving IRF3
(25). In this context, it is
notable that an HSV mutant, lacking a leaky late gene γ134.5,
replicates efficiently in cells devoid of IFN-α/β genes
(26). Additionally, the
γ134.5 null mutant induces differential cytokine expression
as compared with wild type virus
(27). Thus, HSV modulation of
cytokine expression is a complex process that involves multiple viral
components. Currently, the molecular mechanism governing this event is
unclear. In this study, we show that HSV γ134.5 targets TBK1
and inhibits antiviral signaling. The data herein reveal a previously
unrecognized mechanism by which γ134.5 facilitates HSV
replication. 相似文献
15.
Zhemin Zhou Yoshiteru Hashimoto Michihiko Kobayashi 《The Journal of biological chemistry》2009,284(22):14930-14938
16.
Yamini S. Bynagari Bela Nagy Jr. Florin Tuluc Kamala Bhavaraju Soochong Kim K. Vinod Vijayan Satya P. Kunapuli 《The Journal of biological chemistry》2009,284(20):13413-13421
The novel class of protein kinase C (nPKC) isoform η is expressed in
platelets, but not much is known about its activation and function. In this
study, we investigated the mechanism of activation and functional implications
of nPKCη using pharmacological and gene knock-out approaches. nPKCη
was phosphorylated (at Thr-512) in a time- and concentration-dependent manner
by 2MeSADP. Pretreatment of platelets with MRS-2179, a P2Y1
receptor antagonist, or YM-254890, a Gq blocker, abolished
2MeSADP-induced phosphorylation of nPKCη. Similarly, ADP failed to
activate nPKCη in platelets isolated from P2Y1 and
Gq knock-out mice. However, pretreatment of platelets with
P2Y12 receptor antagonist, AR-C69331MX did not interfere with
ADP-induced nPKCη phosphorylation. In addition, when platelets were
activated with 2MeSADP under stirring conditions, although nPKCη was
phosphorylated within 30 s by ADP receptors, it was also dephosphorylated by
activated integrin αIIbβ3 mediated outside-in
signaling. Moreover, in the presence of SC-57101, a
αIIbβ3 receptor antagonist, nPKCη
dephosphorylation was inhibited. Furthermore, in murine platelets lacking
PP1cγ, a catalytic subunit of serine/threonine phosphatase,
αIIbβ3 failed to dephosphorylate nPKCη.
Thus, we conclude that ADP activates nPKCη via P2Y1 receptor
and is subsequently dephosphorylated by PP1γ phosphatase activated by
αIIbβ3 integrin. In addition, pretreatment of
platelets with η-RACK antagonistic peptides, a specific inhibitor of
nPKCη, inhibited ADP-induced thromboxane generation. However, these
peptides had no affect on ADP-induced aggregation when thromboxane generation
was blocked. In summary, nPKCη positively regulates agonist-induced
thromboxane generation with no effects on platelet aggregation.Platelets are the key cellular components in maintaining hemostasis
(1). Vascular injury exposes
subendothelial collagen that activates platelets to change shape, secrete
contents of granules, generate thromboxane, and finally aggregate via
activated αIIbβ3 integrin, to prevent further
bleeding (2,
3). ADP is a physiological
agonist of platelets secreted from dense granules and is involved in feedback
activation of platelets and hemostatic plug stabilization
(4). It activates two distinct
G-protein-coupled receptors (GPCRs) on platelets, P2Y1 and
P2Y12, which couple to Gq and Gi,
respectively
(5–8).
Gq activates phospholipase Cβ (PLCβ), which leads to
diacyl glycerol (DAG)2
generation and calcium mobilization
(9,
10). On the other hand,
Gi is involved in inhibition of cAMP levels and PI 3-kinase
activation (4,
6). Synergistic activation of
Gq and Gi proteins leads to the activation of the
fibrinogen receptor integrin αIIbβ3.
Fibrinogen bound to activated integrin αIIbβ3
further initiates feed back signaling (outside-in signaling) in platelets that
contributes to the formation of a stable platelet plug
(11).Protein kinase Cs (PKCs) are serine/threonine kinases known to regulate
various platelet functional responses such as dense granule secretion and
integrin αIIbβ3 activation
(12,
13). Based on their structure
and cofactor requirements, PKCs are divided in to three classes: classical
(cofactors: DAG, Ca2+), novel (cofactors: DAG) and atypical
(cofactors: PIP3) PKC isoforms
(14). All the members of the
novel class of PKC isoforms (nPKC), viz. nPKC isoforms δ, θ,
η, and ε, are expressed in platelets
(15), and they require DAG for
activation. Among all the nPKCs, PKCδ
(15,
16) and PKCθ
(17–19)
are fairly studied in platelets. Whereas nPKCδ is reported to regulate
protease-activated receptor (PAR)-mediated dense granule secretion
(15,
20), nPKCθ is activated
by outside-in signaling and contributes to platelet spreading on fibrinogen
(18). On the other hand, the
mechanism of activation and functional role of nPKCη is not addressed as
yet.PKCs are cytoplasmic enzymes. The enzyme activity of PKCs is modulated via
three mechanisms (14,
21): 1) cofactor binding: upon
cell stimulus, cytoplasmic PKCs mobilize to membrane, bind cofactors such as
DAG, Ca2+, or PIP3, release autoinhibition, and attain an active
conformation exposing catalytic domain of the enzyme. 2) phosphorylations:
3-phosphoinositide-dependent kinase 1 (PDK1) on the membrane phosphorylates
conserved threonine residues on activation loop of catalytic domain; this is
followed by autophosphorylations of serine/threonine residues on turn motif
and hydrophobic region. These series of phosphorylations maintain an active
conformation of the enzyme. 3) RACK binding: PKCs in active conformation bind
receptors for activated C kinases (RACKs) and are lead to various subcellular
locations to access the substrates
(22,
23). Although various leading
laboratories have elucidated the activation of PKCs, the mechanism of
down-regulation of PKCs is not completely understood.The premise of dynamic cell signaling, which involves protein
phosphorylations by kinases and dephosphorylations by phosphatases has gained
immense attention over recent years. PP1, PP2A, PP2B, PHLPP are a few of the
serine/threonine phosphatases reported to date. Among them PP1 and PP2
phosphatases are known to regulate various platelet functional responses
(24,
25). Furthermore, PP1c, is the
catalytic unit of PP1 known to constitutively associate with
αIIb and is activated upon integrin engagement with
fibrinogen and subsequent outside-in signaling
(26). Among various PP1
isoforms, recently PP1γ is shown to positively regulate platelet
functional responses (27).
Thus, in this study we investigated if the above-mentioned phosphatases are
involved in down-regulation of nPKCη. Furthermore, reports from other cell
systems suggest that nPKCη regulates ERK/JNK pathways
(28). In platelets ERK is
known to regulate agonist induced thromboxane generation
(29,
30). Thus, we also
investigated if nPKCη regulates ERK phosphorylation and thereby
agonist-induced platelet functional responses.In this study, we evaluated the activation of nPKCη downstream of ADP
receptors and its inactivation by an integrin-associated phosphatase
PP1γ. We also studied if nPKCη regulates functional responses in
platelets and found that this isoform regulates ADP-induced thromboxane
generation, but not fibrinogen receptor activation in platelets. 相似文献
17.
18.
Kelly J. Inglis David Chereau Elizabeth F. Brigham San-San Chiou Susanne Sch?bel Normand L. Frigon Mei Yu Russell J. Caccavello Seth Nelson Ruth Motter Sarah Wright David Chian Pamela Santiago Ferdie Soriano Carla Ramos Kyle Powell Jason M. Goldstein Michael Babcock Ted Yednock Frederique Bard Guriqbal S. Basi Hing Sham Tamie J. Chilcote Lisa McConlogue Irene Griswold-Prenner John P. Anderson 《The Journal of biological chemistry》2009,284(5):2598-2602
Several neurological diseases, including Parkinson disease and dementia
with Lewy bodies, are characterized by the accumulation of α-synuclein
phosphorylated at Ser-129 (p-Ser-129). The kinase or kinases responsible for
this phosphorylation have been the subject of intense investigation. Here we
submit evidence that polo-like kinase 2 (PLK2, also known as serum-inducible
kinase or SNK) is a principle contributor to α-synuclein phosphorylation
at Ser-129 in neurons. PLK2 directly phosphorylates α-synuclein at
Ser-129 in an in vitro biochemical assay. Inhibitors of PLK kinases
inhibited α-synuclein phosphorylation both in primary cortical cell
cultures and in mouse brain in vivo. Finally, specific knockdown of
PLK2 expression by transduction with short hairpin RNA constructs or by
knock-out of the plk2 gene reduced p-Ser-129 levels. These results
indicate that PLK2 plays a critical role in α-synuclein phosphorylation
in central nervous system.The importance of α-synuclein to the pathogenesis of Parkinson
disease (PD)4 and the
related disorder, dementia with Lewy bodies (DLB), is suggested by its
association with Lewy bodies and Lewy neurites, the inclusions that
characterize these diseases
(1–3),
and demonstrated by the existence of mutations that cause syndromes mimicking
sporadic PD and DLB
(4–6).
Furthermore, three separate mutations cause early onset forms of PD and DLB.
It is particularly telling that duplications or triplications of the gene
(7–9),
which increase levels of α-synuclein with no alteration in sequence,
also cause PD or DLB.α-Synuclein has been reported to be phosphorylated on serine
residues, at Ser-87 and Ser-129
(10), although to date only
the Ser-129 phosphorylation has been identified in the central nervous system
(11,
12). Phosphorylation at
tyrosine residues has been observed by some investigators
(13,
14) but not by others
(10–12).
Phosphorylation at Ser-129 (p-Ser-129) is of particular interest because the
majority of synuclein in Lewy bodies contains this modification
(15). In addition, p-Ser-129
was found to be the most extensive and consistent modification in a survey of
synuclein in Lewy bodies (11).
Results have been mixed from studies investigating the function of
phosphorylation using S129A and S129D mutations to respectively block and
mimic the modification. Although the phosphorylation mimic was associated with
pathology in studies in Drosophila
(16) and in transgenic mouse
models (17,
18), studies using
adeno-associated virus vectors to overexpress α-synuclein in rat
substantia nigra found an exacerbation of pathology with the S129A mutation,
whereas the S129D mutation was benign, if not protective
(19). Interpretation of these
studies is complicated by a recent study showing that the S129D and S129A
mutations themselves have effects on the aggregation properties of
α-synuclein independent of their effects on phosphorylation, with the
S129A mutation stimulating fibril formation
(20). Clearly, determination
of the role of p-Ser-129 phosphorylation would be helped by identification of
the responsible kinase. In addition, identification will provide a
pathologically relevant way to increase phosphorylation in a cell or animal
model.Several kinases have been proposed to phosphorylate α-synuclein,
including casein kinases 1 and 2
(10,
12,
21) and members of the
G-protein-coupled receptor kinase family
(22). In this report, we offer
evidence that a member of the polo-like kinase (PLK) family, PLK2 (or
serum-inducible kinase, SNK), functions as an α-synuclein kinase. The
ability of PLK2 to directly phosphorylate α-synuclein at Ser-129 is
established by overexpression in cell culture and by in vitro
reaction with the purified kinase. We show that PLK2 phosphorylates
α-synuclein in cells, including primary neuronal cultures, using a
series of kinase inhibitors as well as inhibition of expression with RNA
interference. In addition, inhibitor and knock-out studies in mouse brain
support a role for PLK2 as an α-synuclein kinase in vivo. 相似文献
19.
Sharareh Emadi Srinath Kasturirangan Min S. Wang Philip Schulz Michael R. Sierks 《The Journal of biological chemistry》2009,284(17):11048-11058
Neuropathologic and genetics studies as well as transgenic animal models
have provided strong evidence linking misfolding and aggregation of
α-synuclein to the progression of Parkinson disease (PD) and other
related disorders. A growing body of evidence implicates various oligomeric
forms of α-synuclein as the toxic species responsible for
neurodegeneration and neuronal cell death. Although numerous different
oligomeric forms of α-synuclein have been identified in vitro,
it is not known which forms are involved in PD or how, when, and where
different forms contribute to the progression of PD. Reagents that can
interact with specific aggregate forms of α-synuclein would be very
useful not only as tools to study how different aggregate forms affect cell
function, but also as potential diagnostic and therapeutic agents for PD. Here
we show that a single chain antibody fragment (syn-10H scFv) isolated from a
phage display antibody library binds to a larger, later stage oligomeric form
of α-synuclein than a previously reported oligomeric specific scFv
isolated in our laboratory. The scFv described here inhibits aggregation of
α-synuclein in vitro, blocks extracellular
α-synuclein-induced toxicity in both undifferentiated and differentiated
human neuroblastoma cell lines (SH-SY5Y), and specifically recognizes
naturally occurring aggregates in PD but not in healthy human brain
tissue.Parkinson disease
(PD)2 is the second
most common neurodegenerative disorder of the elderly, affecting more than
500,000 people in the United States
(1), with 50,000 new cases
reported each year at an annual cost estimated at 10 billion dollars per year.
Pathologically, PD is characterized by the progressive loss of dopaminergic
neurons in the substantia nigra and formation of fibrillar cytoplasmic
inclusions known as Lewy bodies and Lewy neurites
(2,
3). The protein
α-synuclein has been strongly linked to PD
(4,
5) and other related
neurodegenerative disorders (6,
7) by several lines of
evidence. 1) It is the major component of the hallmark Lewy body aggregates
associated with PD. 2) Mutations (A53T, A30P, and E46K, where A30P is human
A30P α-synuclein; A53T is human A53T α-synuclein; E46K is human
E46K α-synuclein) or multiplication in the α-synuclein gene have
been linked to familial PD
(8–10).
3) Overexpression of α-synuclein in transgenic mice and
Drosophila has been shown to induce the formation of PD-like
pathological phenotypes and behavior, although the animal models do not in
general replicate neuronal loss patterns
(11,
12).α-Synuclein is a small protein (14 kDa) expressed mainly in brain
tissues and is primarily localized at the presynaptic terminals of neurons
(13). The primary structure of
α-synuclein consists of three distinct regions. The N-terminal region of
α-synuclein includes the mutation sites associated with familial PD
(A53T, A30P, and E46K) and contains six imperfectly conserved repeats (KTKEGV)
that may facilitate protein-protein binding. This repeat section is predicted
to form amphipathic α-helices, typical of the lipid-binding domain of
apolipoproteins (14). The
central region, non-amyloid component, is extremely hydrophobic and includes a
12-residue stretch (VTGVTAVAQKTV) that is essential for aggregation
(15). The C-terminal region is
enriched with acidic glutamate and aspartate residues and is responsible for
the chaperone function of α-synuclein
(16).α-Synuclein normally exists as an unfolded protein, but it can adopt
several different folded conformations depending on the environment, including
small aggregates or oligomers, spherical and linear protofibrils, as well as
the fibrillar structure found in Lewy bodies
(14,
15). A growing body of
evidence implicates the oligomeric forms of α-synuclein as the toxic
species responsible for neurodegeneration and neuronal cell death
(16–18).
Several different oligomeric forms of α-synuclein including spherical,
annular (19), pore-like
(20), and dopamine-stabilized
structures have been identified in vitro
(21).α-Synuclein is considered a cytosolic protein, and consequently its
pathogenic effect was assumed to be limited to the cytoplasm of single cells.
However, recent studies have suggested that α-synuclein also has
extracellular pathogenic effects
(22–25).
α-Synuclein was detected in blood plasma and cerebrospinal fluid in both
monomeric and oligomeric forms
(22–25),
and the presence of significantly elevated levels of oligomeric species of
α-synuclein has been reported extracellularly in plasma and
cerebrospinal fluid samples from patients with PD
(23). Furthermore, various
studies have shown that aggregated α-synuclein added extracellularly to
the culture medium is cytotoxic
(26–32).Despite all these studies, it is still not clear how the various aggregate
forms of α-synuclein are involved in the progression of PD. Therefore,
reagents that can interact with specific aggregate forms of α-synuclein
would be very useful not only for fundamental studies of how α-synuclein
aggregates affect cell function but also as potential diagnostic and
therapeutic agents for PD.Recently, we reported inhibition of both aggregation and extracellular
toxicity of α-synuclein in vitro by a single chain variable
domain antibody fragment (scFv) that specifically recognized an oligomeric
form of α-synuclein
(32). In this study, we
describe a second scFv (syn-10H) that binds a larger later stage oligomeric
form of α-synuclein than the previously reported scFv. The syn-10H scFv
neutralizes α-synuclein-induced toxicity in both undifferentiated and
differentiated SH-SY5Y human neuroblastoma cell line and inhibits
α-synuclein aggregation in vitro. The syn-10H scFv reacts
specifically with homogenized PD brain tissue but does not cross-react with
similarly treated samples taken from Alzheimer disease (AD) or healthy brain
samples. Such scFvs therefore have potential value as diagnostic reagents to
identify the presence of specific oligomeric species in PD tissue and fluid
samples. The scFvs also have value as therapeutic agents as they can be used
either extracellularly or expressed intracellularly (intrabodies) to prevent
formation of toxic aggregates in vivo whether inside or outside of
cells. Intrabodies have been used efficiently to neutralize toxic effects of
different pathogenic agents, including α-synuclein
(33–36).
Moreover, immunization studies in mouse models of PD have shown that
extracellular antibodies can reduce accumulation of intracellular aggregates
of α-synuclein (37),
thereby providing precedent for the use of scFvs in potential passive
vaccination strategies for treating PD. 相似文献
20.
Guo-Dong Li David C. Chiara Jonathan B. Cohen Richard W. Olsen 《The Journal of biological chemistry》2009,284(18):11771-11775
Photoaffinity labeling of γ-aminobutyric acid type A
(GABAA)-receptors (GABAAR) with an etomidate analog and
mutational analyses of direct activation of GABAAR by neurosteroids
have each led to the proposal that these structurally distinct general
anesthetics bind to sites in GABAARs in the transmembrane domain at
the interface between the β and α subunits. We tested whether the
two ligand binding sites might overlap by examining whether neuroactive
steroids inhibited etomidate analog photolabeling. We previously identified
(Li, G. D., Chiara, D. C., Sawyer, G. W., Husain, S. S., Olsen, R. W., and
Cohen, J. B. (2006) J. Neurosci. 26, 11599–11605) azietomidate
photolabeling of GABAAR α1Met-236 and βMet-286 (in
αM1 and βM3). Positioning these two photolabeled amino acids in a
single type of binding site at the interface of β and α subunits
(two copies per pentamer) is consistent with a GABAAR homology
model based upon the structure of the nicotinic acetylcholine receptor and
with recent αM1 to βM3 cross-linking data. Biologically active
neurosteroids enhance rather than inhibit azietomidate photolabeling, as
assayed at the level of GABAAR subunits on analytical SDS-PAGE, and
protein microsequencing establishes that the GABAAR-modulating
neurosteroids do not inhibit photolabeling of GABAAR
α1Met-236 or βMet-286 but enhance labeling of α1Met-236. Thus
modulatory steroids do not bind at the same site as etomidate, and neither of
the amino acids identified as neurosteroid activation determinants (Hosie, A.
M., Wilkins, M. E., da Silva, H. M., and Smart, T. G. (2006) Nature
444, 486–489) are located at the subunit interface defined by our
etomidate site model.GABAA3
receptors (GABAAR) are major mediators of brain inhibitory
neurotransmission and participate in most circuits and behavioral pathways
relevant to normal and pathological function
(1). GABAAR are
subject to modulation by endogenous neurosteroids, as well as myriad
clinically important central nervous system drugs including general
anesthetics, benzodiazepines, and possibly ethanol
(1,
2). The mechanism of
GABAAR modulation by these different classes of drugs is of major
interest, including identification of the receptor amino acid residues
involved in binding and action of the drugs.In the absence of high resolution crystal structures of drug-receptor
complexes, the locations of anesthetic binding sites in GABAARs
have been predicted based upon analyses of functional properties of point
mutant receptors, which identified residues in the α and β subunit
M1–M4 transmembrane helices important for modulation by volatile
anesthetics (primarily α subunit) and by intravenous agents, including
etomidate and propofol (β subunit)
(3–5).
Position βM2–15, numbered relative to the N terminus of the helix,
functions as a major determinant of etomidate and propofol potency as GABA
modulators in vitro and in vivo
(6–8).
By contrast, this residue is not implicated for modulation by the
neurosteroids, potent endogenous modulators of GABAAR
(9).Photoaffinity labeling, which allows the identification of residues in
proximity to drug binding sites
(10,
11), has been used to identify
two GABAAR amino acids covalently modified by the etomidate analog
[3H]azietomidate
(12): α1Met-236 within
αM1 and βMet-286 within βM3. Photolabeling of these residues
was inhibited equally by nonradioactive etomidate and enhanced proportionately
by GABA present in the assay, consistent with the presence of these two
residues in a common drug binding pocket that would be located at the
interface between the β and α subunits in the transmembrane domain
(12). Mutational analyses
identify these positions as etomidate and propofol sensitivity determinants
(13–15).A recent mutagenesis study
(16) identified two other
residues in GABAAR αM1 and βM3 as critical for direct
activation by neurosteroids, αThr-236 (rat numbering, corresponding to
α1Thr-237, bovine numbering used here and by Li et al.
(12))4
and βTyr-284. These residues were also proposed to contribute to a
neurosteroid binding pocket in the transmembrane domain at the interface
between β and α subunits, based upon their location in an
alternative GABAAR structural model that positioned those amino
acids, and not α1Met-236 or βMet-286, at the subunit interface. For
GABAARs and other members of the Cys-loop superfamily of
neurotransmitter-gated ion channels, the transmembrane domain of each subunit
is made up of a loose bundle of four α helices (M1–M4), with M2
from each subunit contributing to the lumen of the ion channel and M4
positioned peripherally in greatest contact with lipid, as seen in the
structures of the Torpedo nicotinic acetylcholine receptor (nAChR)
(17) and in distantly related
prokaryote homologs (18).
However, uncertainties in the alignment of GABAAR subunit sequences
relative to those of the nAChR result in alternative GABAAR
homology models (12,
19,
20) that differ in the
location of amino acids in the M3 and M4 membrane-spanning helices and in the
M1 helix in some models (16,
21).If etomidate and neurosteroids both bind at the same β/α
interface in the GABAAR transmembrane domain, the limited space
available for ligand binding suggests that their binding pockets might overlap
and that ligand binding would be mutually exclusive. To address this question,
we photolabeled purified bovine brain GABAAR with
[3H]azietomidate in the presence of different neuroactive steroids
and determined by protein microsequencing whether active neurosteroids
inhibited labeling of α1Met-236 and βMet-286, as expected for
mutually exclusive binding, or resulted in [3H]azietomidate
photolabeling of other amino acids, a possible consequence of allosteric
interactions. Active steroids failed to inhibit labeling and enhanced labeling
of α1Met-236, clearly indicating that the neurosteroid and the etomidate
sites are distinct. Our GABAAR homology model that positions
α1Met-236 and βMet-286 at the β/α interface, but not
that of Hosie et al.
(16), is also consistent with
cysteine substitution cross-linking studies
(20,
22), which define the
proximity relations between amino acids in the αM1, αM2,
αM3, and βM3 helices, and these results support the interpretation
that the two residues photolabeled by [3H]azietomidate are part of
a single subunit interface binding pocket, whereas the steroid sensitivity
determinants identified by mutagenesis neither are at the β/α
subunit interface nor are contributors to a common binding pocket. 相似文献